Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study.

Takeshi KatoYoshinori KagawaYasutoshi KubokiMakio GamohYoshito KomatsuHirofumi YasuiHironaga SatakeEiji OkiHiroaki TaniokaMasahito KotakaAkitaka MakiyamaTadamichi DendaMasahiro GotoTakayuki YoshinoKentaro YamazakiJunpei SoedaKazunori ShibuyaMasaru IwataKoji ObaKensei Yamaguchi

Published in: International journal of clinical oncology (2021)

Panitumumab plus FTD/TPI exhibited favourable anti-tumour activity with a manageable safety profile and may be a therapeutic option for pre-treated mCRC patients.

Keyphrases

metastatic colorectal cancer
wild type
newly diagnosed
end stage renal disease
chronic kidney disease
ejection fraction
prognostic factors
squamous cell carcinoma
patient reported outcomes
radiation therapy
patient reported